Targeting RAF dimers in RAS mutant tumors: From biology to clinic
RAS mutations occur in approximately 30% of tumors worldwide and have a poor prognosis due to limited therapies. Covalent targeting of KRAS G12C has achieved significant success in recent years, but there is still a lack of efficient therapeutic approaches for tumors with non-G12C KRAS mutations. A...
| Published in: | Acta Pharmaceutica Sinica B |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-05-01
|
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221138352400056X |